Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation TCT 2025

Optimizing PCI Outcomes After ACS: Lipid Modification Therapies - LDL, Lp(a) and Beyond

Presenter: Marc P. Bonaca

October 27, 2025

Presentation TCT 2025

TCT 758: Lp(a) and Oxidized Phospholipids as Predictors of Bioprosthetic Valve Dysfunction Following Transcatheter Aortic Valve Implantation

Presenter: Frédéric Beaupré

October 27, 2025

Presentation TCT 2025

TCT 471: Pericoronary Fat Attenuation Index Combined with Lp(a) for Predicting Post-PCI Adverse Outcomes in Coronary Artery Disease Patients

Presenter: Zixiang Ye

October 27, 2025

Presentation TCT 2025

ACS Pharma Trials On The Horizon: Other Lipid Targets - Lpa and CETP Inhibitors

Presenter: Dharam J. Kumbhani

October 26, 2025

Presentation TCT 2019

LP(a): Not So Little Anymore

Presenter: Roberta Rossini

September 26, 2019

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2014

LpPLA2 Inhibition by Darapladib in Coronary Artery Disease: Game Over or Just Beginning?

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran

September 15, 2014

Advertisement

Optimizing PCI Outcomes After ACS: Lipid Modification Therapies - LDL, Lp(a) and Beyond

TCT 758: Lp(a) and Oxidized Phospholipids as Predictors of Bioprosthetic Valve Dysfunction Following Transcatheter Aortic Valve Implantation

TCT 471: Pericoronary Fat Attenuation Index Combined with Lp(a) for Predicting Post-PCI Adverse Outcomes in Coronary Artery Disease Patients

ACS Pharma Trials On The Horizon: Other Lipid Targets - Lpa and CETP Inhibitors

LP(a): Not So Little Anymore

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

LpPLA2 Inhibition by Darapladib in Coronary Artery Disease: Game Over or Just Beginning?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content